IARJSET ISSN (O) 2393-8021, ISSN (P) 2394-1588

International Advanced Research Journal in Science, Engineering and Technology

ISO 3297:2007 Certified ⁜ Impact Factor 8.066 ⁜ Peer-reviewed / Refereed journal ⁜ Vol. 10, Issue 6, June 2023

DOI: 10.17148/IARJSET.2023.10623

Recent Advances Transdermal Dermal Delivery System

Vikas Kaushal[1], Mrs.Pooja Sharma[2], Dr. Rajesh Gupta[3], Dr. Nitian Bharti Gupta[4]

Department of Pharmaceutics, Sri Sai College of Pharmacy, Badhani, Pathankot, 145001, Punjab, India[1-4]

Abstract: Colorful non-invasive administrations have lately surfaced as an volition to conventional needle injections. A transdermal medicine delivery system (TDDS) represents the most seductive system among these because of its low rejection rate, excellent ease of administration, and superb convenience and continuity among cases. TDDS could be applicable in not only medicinals but also in the skin care assiduity, including cosmetics. Because this method substantially involves original administration, it can help original buildup in medicine attention and nonspecific delivery to apkins not targeted by the medicine. still, the physicochemical parcels of the skin restate to multiple obstacles and restrictions in transdermal delivery, with multitudinous examinations conducted to overcome these backups. In this review, we describe the different types of available TDDS styles, along with a critical discussion of the specific advantages and disadvantages, characterization styles, and eventuality of each method. Progress in exploration on these indispensable styles has established the high effectiveness essential to TDDS, which is expected to find operations in a wide range of fields.

Keywords: Transdermal medicine delivery, Skin, Active/ unresistant system, Characterization

I. INTRODUCTION

Medicine delivery system(DDS) is a general term for a series of physicochemical technologies that can control delivery and release of pharmacologically active substances into cells, apkins and organs, similar that these active substances could ply optimal goods(1, 2). In other words, DDS covers the routes of administration and medicine phrasings that efficiently deliver the medicine to maximize remedial efficacity while minimizing any side effect(3 – 5). Depending on the delivery route, there are numerous types of administration modalities, similar as oral administration, transdermal administration, lung inhalation, mucosal administration, and intravenous injection. Among them, the transdermal medicine delivery system(TDDS) represents an seductive approach. TDDS has come one of the most extensively delved routes of noninvasive medicine delivery into the body through the skin, unlike conventionally used direct administration routes that make use of needle- grounded injections. TDDS has significantly told the delivery of colorful remedial agents, especially in pain operation, hormonal remedy, and treatment of conditions of the cardiovascular and central nervous systems(6 – 9). TDDS doesn't involve passage through the gastrointestinal tract; thus, there's no loss due to first- pass metabolism, and medicines can be delivered without hindrance from pH, enzymes, and intestinal bacteria. In addition, TDDS can be used to control medicine release according to operation restrictions, thereby contributing to the high continuity of this system. Most importantly, because TDDS is a noninvasive administration system and involves minimum pain and burden on the case, medicines can be safely and accessibly administered to children or the senior(10 – 12).



Fig.1 Structure of Skin

IARJSET ISSN (O) 2393-8021, ISSN (P) 2394-1588

International Advanced Research Journal in Science, Engineering and Technology

ISO 3297:2007 Certified ⁜ Impact Factor 8.066 ⁜ Peer-reviewed / Refereed journal ⁜ Vol. 10, Issue 6, June 2023

DOI: 10.17148/IARJSET.2023.10623

Still, it still doesn't use its full eventuality due to the ingrain skin hedge. The skin is the remotest organ with amulti-layered structure, and the part of the skin is to cover our body by blocking environmental hazards similar as chemicals, heat, and poisons(13, 14). Fig. 1). similar skin can be divided into the epidermis, which has the defensive function, and the dermis, where blood vessels are located, and produces skin cells, and each subcaste has rudiments that intrude with transdermal delivery. First, the skin hedge effect of the epidermis occurs in the stratum corneum, the remotest subcaste, and is a property of blocking external substances. The hedge effect is veritably significant in the transport of substances having a large molecular weight. In TDDS, it's generally accepted that the delivery of substances with small molecular weights utilizes the intracellular pathway. still, for substances having a large molecular weight, styles and colorful mechanisms using the intracellular pathway in addition to the intercellular pathway are introduced and used(15 – 17). This is due to the structure of the skin because the part called lipid containing both cells and hydrophilic substances and hydrophobic substances does not have a impeccably regular position but exists with chronicity(18).

Enhancement of transdermal delivery by equipment (active delivery)

Iontophoresis promotes the movement of ions across the membrane under the influence of a small externally applied potential difference (less than 0.5 mA/cm2), which has been proven to enhance skin penetration and increase release rate of several drugs with poor absorption/permeation profiles. This technique has been utilized in the in vivo transport of ionic or nonionic drugs by the application of an electrochemical potential gradient [25]. The efficacy of iontophoresis depends on the polarity, valency, and mobility of the drug molecule, the nature of the applied electrical cycle, and the formulation containing the drug. In particular, the dependence on current makes drug absorption through iontophoresis less dependent on biological parameters, unlike most other drug delivery systems [26]. This modality could additionally include electronic means of reminding patients to change dosages, if desired, to increase patient compliance [27, 28].

Sonophoresis The desired range of ultrasound frequencies generated by an ultrasound device can improve transdermal drug delivery [29, 30]. Low-frequency ultrasound is more effective, because it facilitates drug movement by creatingan aqueous path in the perturbed bilayer through cavitation [31]. The drug under consideration is mixed with a specific coupler, such as a gel or a cream, which transmits ultrasonic waves to the skin and disturbs the skin layers, thereby creating an aqueous path through which the drug can be injected. Drugs typically pass through passages created by the application of ultrasonic waves with energy values between 20 kHz and 16 MHz. Ultrasound also increases the local temperature of the skin area and creates a thermal effect, which further promotes drug penetration. Several drugs of different classes have been delivered by this method regardless of their solubility, dissociation and ionization constants, and electrical properties (including hydrophilicity), such as mannitol and high molecular weight (MW) drugs such as insulin.

Electroporation This method uses the application of high voltage electric pulses ranging from 5 to 500 V for short exposure times (~ms) to the skin, which leads to the formation of small pores in the SC that improve permeability and aid drug diffusion [32,33]. For safe and painless drug administration, electric pulses are introduced using closely positioned electrodes. This is a very safe and painless procedure involving permeabilization of the skin and has been used to demonstrate the successful delivery of not only low MW drugs, such as doxorubicin, mannitol, or calcein, but also high MW ones such as antiangiogenic peptides, oligonucleotides, and the negatively charged anticoagulant heparin. However, this method has the disadvantages of small delivery loads, massive cellular perturbation sometimes including cell death, heatinginduced drug damage, and denaturation of protein and other biomacromolecular therapeutics.

TDDS using chemical enhancers (passive delivery) To achieve enhanced transdermal delivery and therapeutic efficacy, drugs should have low MW (less than 1 kDa), an affinity for lipophilic and hydrophilic phases, short half-life, and a lack of skin irritability [34]. Many factors affect drug penetration through the skin, such as species differences, skin age and site, skin temperature, state of the skin, area of application, duration of exposure, moisture content of the skin, pretreatment methods, and physical characteristics of the penetrant.

Recent studies that have focused on aspects of transdermal drug delivery technologies ranging from the development of chemical enhancers that increase the spread of drugs across the skin or increase the solubility of drugs in the skin to novel innovative approaches that extend this concept to the design of super-strong formulations, microemulsions, and vesicles [35, 36].Penetration enhancers can be used alone or in combination with chemical penetration enhancers with proven superior skin penetration as compared to that of individual chemicals. These synergistic systems include eutectic mixtures and nanoparticle composite self-assembled vesicles. Therefore, research in recent years have focused on the application of suitable molecular simulation methodologies in understanding the skin lipid barrier, mechanisms regulating penetration of molecules across the skin and transport of penetration enhancers, and perturbations in the skin barrier function.

IARJSET ISSN (O) 2393-8021, ISSN (P) 2394-1588

International Advanced Research Journal in Science, Engineering and Technology

ISO 3297:2007 Certified ⁜ Impact Factor 8.066 ⁜ Peer-reviewed / Refereed journal ⁜ Vol. 10, Issue 6, June 2023

DOI: 10.17148/IARJSET.2023.10623

Advantages of Transdermal Drug Delivery System [37,38]

. Transdermal drug delivery system can be very helpful in avoiding many difficulties that are faced by the drug delivery system of other routes like g.i.t. pH, and enzymes and food and drinks etc.
. Transdermal drug delivery system can be a good substitute route for drugs that cause nausea and/or vomiting upon administration with oral route.
. This route is excellent for drugs that are prone to 1st pass metabolism.
. The known invasive nature of this system is one of the main reasons of its acceptability.
. The therapy can be sustained for long duration with only single application, this help in improving patient compliance.
. Drug who have shot life can be given through this route by reservoir system.
. Termination of therapy in case of adverse event is easy without any harm to the patient.

Disadvantages of Transdermal Drug Delivery System [37,38,39]

Relatively potent therapeutic moiety do considered as suitable participant for transdermal drug delivery system.
. Some patient may suffer from post therapy side effect like dermatitis at the site of application.
. Ionic drugs are not suitable for this route.
. High plasma concentration of drug through this route cannot be achieved.
. Drugs that has large surface area cannot be used for this route.
. Drugs that causes skin irritation cannot be given by this room.

Methods for characterizing TDDS The evaluation of delivery efficiency and effectiveness is a very important process in TDDS. There are various methods used for this, depending on the type and purpose of the drug to be delivered. However, the three most common methods involve the use of diffusion cells, tape stripping, and microscopic and spectroscopic examination [40,41], in which each method makes use of a distinct analysis method. As the drug applied to the surface is absorbed, all these characterization methods are based on the principle of measuring the amount of the drug in each surface layer or storing an imaging material instead the drug to visually confirm the absorption behavior. Diffusion cell method Tests employing diffusion cells represent the gold standard in the evaluation of TDDS, with Franz diffusion cells being the most common used setup [42,43].

This technique determines important relationships among the skin, active pharmaceutical ingredients, and the nature of the formulation. The diffusion cell consists of a chamber for drug application, a membrane within which the drug may diffuse, and an acceptor media chamber from which samples may be investigated. Diffusion cells are categorized into two main classes, namely, static and flow-through cells. In static cells, as in the popular Franz diffusion cell, the donor, the membrane, and the acceptor modules could be placed either vertically or horizontally.

There are Franz cells that open from above; therefore, the measurement runs under conditions of atmospheric pressure. However, most of these cells are closed from the top, leading to increased pressure, which translates to an overestimation of penetration values. Nowadays, “hand-sampler” Franz diffusion cells have been replaced by systems connected to an automated sampler. These automated sampling systems facilitate the work of researchers and reduce errors from manually conducted experiments.

Tape stripping

Tape stripping is a commonly used minimally invasive method to test the penetration of topically applied formulations through the SC, where a layer of the SC is removed with an adhesive tape followed by examination of the skin layer on the adhesive tape [44,45,46,47]. The tape stripping process is performed after an appropriate incubation time post topical application of the test composition. The composition may be removed or left on the skin to provide the original amount of components to be used during the measurement. The adhesive tape is placed on the skin surface and is always removed from the same selection. It is important that the adhesive tape is always flattened with the same force as the roller to eliminate the effect of creases and recesses on tape stripping. In addition, the removal rate is an important factor.

The slower the adhesive tape removal rate, the higher the adhesion of the SC to the patch, which increases the amount of skin removed from the patch. The removed adhesive tape contains both the SC layer and the active ingredients of the composition used. Several methods can be used to test samples harvested using adhesive tape. High-performance liquid chromatography (HPLC) analysis produces quantitative results, whereas spectroscopic methods produce semiquantitative insights. During HPLC analysis, the test material on the adhesive tape is extracted and analyzed on chromatographic separation. It is also possible to detect active substances using atomic absorption spectroscopy. However, the most prevalent method used to characterize skin harvested by tape stripping is attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR).

IARJSET ISSN (O) 2393-8021, ISSN (P) 2394-1588

International Advanced Research Journal in Science, Engineering and Technology

ISO 3297:2007 Certified ⁜ Impact Factor 8.066 ⁜ Peer-reviewed / Refereed journal ⁜ Vol. 10, Issue 6, June 2023

DOI: 10.17148/IARJSET.2023.10623

REFERENCES

1. Vega-Vásquez P, Mosier NS, Irudayaraj J. Nanoscale drug delivery systems: from medicine to agriculture. Front Bioeng Biotechnol. 2020;8:79.
2. Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021.
3. Mali AD, Bathe R, Patil M. An updated review on transdermal drug delivery systems. Int J Adv Sci Res. 2015;1(6):244–54.
4. Li C, Wang J, Wang Y, Gao H, Wei G, Huang Y, et al. Recent progress in drug delivery. Acta Pharm Sin B. 2019;9(6):1145–62.
5. Kumar JA, Pullakandam N, Prabu SL, Gopal V. Transdermal drug delivery system: An overview. Int J Pharm Sci Rev Res. 2010;3(2):49–54.
6. Roohnikan M, Laszlo E, Babity S, Brambilla DA. Snapshot of transdermal and tropical drug delivery research in Canada. Pharmaceutics. 2019;11(6):256.
7. Peña-Juárez MC, Guadarrama-Escobar OR, Escobar-Chávez JJ. Transdermal delivery Systems for Biomolecules. J Pharm Innov. 2021;6:1–14.
8. Ali H. Transdermal drug delivery system & patient compliance. MOJ Bioequiv Availab. 2017;3(2):47 8.
9. Leppert W, Malec–Milewska M, Zajaczkowska R, Wordliczek J. Transdermal and Topical Drug Administration in the Treatment of Pain. Molecules. 2018; 23(3):681.
10. Akhter N, Singh V, Yusuf M, Khan RA. Non-invasive drug delivery technology: development and current status of transdermal drug delivery devices, techniques and biomedical applications. Biomed Tech. 2020;65(3): 243–72.
11. Pires LR, Vinayakumar KB, Turos M, Miguel V, Gaspar J. A perspective on microneedle-based drug delivery and diagnostics in Paediatrics. J Pers Med. 2019;9(4):49.
12. Ruby PK, Pathak SM, Aggarwal D. Critical attributes of transdermal drug delivery system (TDDS) – a generic product development review. . Drug Dev Ind Pharm. 2014;40(11):1421–8.
13. Ali S, Shabbir M, Shahid N. The structure of skin and transdermal drug delivery system - a review. Res J Pharm Tech. 2015;8(2):103–9.
14. Wang M, Luo Y, Wang T, Wan C, Pan L, Pan S, et al. Artificial skin perception. Adv Mater. 2020;33:e2003014.
15. Hutton AR, McCrudden MT, Larrañeta E, Donnelly RF. Influence of molecular weight on transdermal delivery of model macromolecules using hydrogelforming microneedles: potential to enhance the administration of novel low molecular weight biotherapeutics. J Mater Chem B. 2020;8(19):4202–9.
16. Andrews SM, Jeong EH, Prausnitz MR. Transdermal delivery of molecules is limited by full epidermis, Not Just Stratum Corneum. Pharm Res. 2013;30(4): 1099–109.
17. Chaulagain B, Jain A, Tiwari A, Verma A, Jain SK. Passive delivery of protein drugs through transdermal route. Artif Cells Nanomed Biotechnol. 2018; 46(1):472–87.
18. Uchechi O, Ogbonna J, Attama AA. Nanoparticles for dermal and transdermal drug delivery. In: Application of nanotechnology in drug delivery. Sezer AD: InTech C; 2014. p. 193–235.
19. Zhou X, Hao Y, Yuan L, Pradhan S, Shrestha K, Pradhan O. Nanoformulations for transdermal drug delivery: a review. Chin Chem Lett. 2018; 29(12):1713–24.
20. Kováčik A, Kopečná M, Vávrová K. Permeation enhancers in transdermal drug delivery: benefits and limitations. Expert Opin Drug Deliv. 2020;17(2): 145–55.
21. Pawar PM, Solanki KP, Mandali VA. Recent advancements in transdermal drug delivery system. Int J Pharm Clin Res. 2018;10(3):65–73.
22. Mujoriya R, Dhamande KA. Review on transdermal drug delivery system. Res J Sci Tech. 2011;3(4):227–31.
23. Patel R, Patel A, Prajapati B, Shinde G, Dharamsi A. Transdermal drug delivery systems: A mini review. Int J Adv Res. 2018;6(5):891–900.
24. Kakar S, Singh R, Rani P. A review on transdermal drug delivery. Innoriginal Int J Sci. 2016;3(4):1–5.
25. Wang Y, Zeng L, Song W, Liu J. Influencing factors and drug application of iontophoresis in transdermal drug delivery: an overview of recent progress. Drug Deliv Transl Res. 2021.
26. Dhal S, Pal K, Giri S. Transdermal delivery of gold nanoparticles by a soybean oil-based oleogel under iontophoresis. ACS Appl Bio Mater. 2020; 3(10):7029–39..
27. Moarefian M, Davalos RV, Tafti DK, Acheniec LE, Jones CN. Modeling iontophoretic drug delivery in a microfluidic device. Lab Chip. 2020;20(18): 3310–21.
28. Byrne JD, Yeh JJ, DeSimone JM. Use of iontophoresis for the treatment of cancer. J Control Release. 2018;284:144–51
29. Park J, Lee H, Lim GS, Kim N, Kim D, Kim YC. Enhanced transdermal drug delivery by sonophoresis and simultaneous application of sonophoresis and iontophoresis. AAPS PharmSciTech. 2019;20(3):96..

DOI: 10.17148/IARJSET.2023.10623

30. Seah BC, Teo BM. Recent advances in ultrasound-based transdermal drug delivery. Int J Nanomedicine. 2018;13:7749–63.
31. Nguyen HX, Banga AK. Electrically and ultrasonically enhanced transdermal delivery of methotrexate. Pharmaceutics. 2018;10(3):117.
32. Charoo NA, Rahman Z, Repka MA, Murthy SN. Electroporation: An avenue for transdermal drug delivery. Curr Drug Deliv. 2010;7(2):125–36.
33. Chen X, Zhu L, Li R, Pang L, Zhu S, Ma J, et al. Electroporation-enhanced transdermal drug delivery: effects of logP, pKa, solubility and penetration time. Eur J Pharm Sci. 2020;151:105410.
34. Stanekzai A, Sudhakar CK, Zhakfar AM, Karan VS. Recent approaches in transdermal drug delivery system. Res J Pharm Tech. 2019;12(9):4550–8.
35. Hadgraft J, Lane ME. Passive transdermal drug delivery systems. Am J Drug Deliv. 2006;4(3):153–60.
36. Gandhi K, Dahiya A, Monika LT, Singh K. Transdermal drug delivery – a review. Int J Res Pharm Sci. 2012;3(3):379–88.
37. Howard C. Ansel, Loyd V. Allen, Jr. Nicholas G. Popovich, Pharmaceutical Dosage Forms and Drug Delivery System, Page no- 263-277.
38. Dipen Patel, Sunita A. Chaudhary, Bhavesh Parmar, Nikunj Bhura,Transdermal Drug Delivery System: A Review. Page no- 1-10.
39. Navneet Kumar Verma, AN OVERVIEW ON TRANSDERMAL PATCHES. Page no- 1-8.
40. Raza R, Mittai A, Kumar P, Alam S, Prakash S, Chauhan N. Approaches and evaluation of transdermal drug delivery system. Int J Drug Dev Res. 2015; 7(1):222–33.
41. Sheth NS, Mistry RB. Formulation and evaluation of transdermal patches and to study permeation enhancement effect of eugenol. J. Appl. Pharm. Sci. 2011;1(3):96–101.
42. Lee JD, Kim JY, Jang HJ, Lee BM, Kim KB. Percutaneous permeability of 1- phenoxy-2-propanol, a preservative in cosmetics. Regul Toxicol Pharmacol. 2019;103:56–62.
43. Rajithaa P, Shammika P, Aiswarya S, Gopikrishnan A, Jayakumar R, Sabitha M. Chaulmoogra oil based methotrexate loaded topical nanoemulsion for the treatment of psoriasis. J Drug Deliv Sci Technol. 2019;49:463–76.
44. Ramadon D, McCrudden MT, Courtenay AJ, Donnelly RF. Enhancement strategies for transdermal drug delivery systems: current trends and applications. Drug Deliv Transl Res. 2021;20:1–34.
45. Salamanca CH, Barrera-Ocampo A, Lasso JC, Camacho N, Yarce CJ. Franz diffusion cell approach for pre-formulation characterisation of ketoprofen semi-solid dosage forms. Pharmaceutics. 2018;10(3):148.
46. Escobar-Chávez JJ, Merino-Sanjuán V, López-Cervantes M, Urban-Morlan Z, Piñón-Segundo E, Quintanar-Guerrero D, et al. The tape-stripping technique as a method for drug quantification in skin. J Pharm Pharm Sci. 2008;11(1): 104–30.
47. Russell LM, Guy RH. Novel imaging method to quantify stratum corneum in dermatopharmacokinetic studies: proof-of-concept with acyclovir formulations. Pharm Res. 2012;29(12):3362–72

